Evidence map›Paper›PMID 33282185›Full record

ArticlePulmonary circulation

Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension.

Anna Hemnes, Alexander M K Rothman, Andrew J Swift, Lawrence S Zisman

Abstract read
In one paragraph

Article in Pulmonary circulation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Review
  3. From Blood to Vessel: Lipid Ratios in Pulmonary Hypertension.American journal of respiratory and critical care medicine · 2025
    Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Phenomic Imaging.Phenomics (Cham, Switzerland) · 2023
    Review
  10. Review
  11. Circulating markers of inflammation and angiogenesis and clinical outcomes across subtypes of pulmonary arterial hypertension.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2023
    Observational
  12. Article
  13. Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension.American journal of respiratory and critical care medicine · 2022
    Article
  14. Review
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Anna HemnesVanderbilt University Medical Center, Nashville, TN, USA.
Alexander M K RothmanUniversity of Sheffield and Sheffield Teaching Hospitals NHS Trust, Sheffield, UK.
Andrew J SwiftUniversity of Sheffield and Sheffield Teaching Hospitals NHS Trust, Sheffield, UK.
Lawrence S ZismanGossamer Bio Inc., San Diego, CA, USA.

Funding

Genomic and Circulating Predictors of PAH responseR01HL142720 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Anna R Hemnes · 2019 to 2026
$5.0M
NHLBI NIH HHS R01 HL142720Wellcome Trust 205188/Z/16/Z
6 · The paper itself

Abstract

Pulmonary arterial hypertension is a complex disease resulting from the interplay of myriad biological and environmental processes that lead to remodeling of the pulmonary vasculature with consequent pulmonary hypertension. Despite currently available therapies, there remains significant morbidity and mortality in this disease. There is great interest in identifying and applying biomarkers to help diagnose patients with pulmonary arterial hypertension, inform prognosis, guide therapy, and serve as surrogate endpoints. An extensive literature on potential biomarker candidates is available, but barriers to the implementation of biomarkers for clinical use in pulmonary arterial hypertension are substantial. Various omic strategies have been undertaken to identify key pathways regulated in pulmonary arterial hypertension that could serve as biomarkers including genomic, transcriptomic, proteomic, and metabolomic approaches. Other biologically relevant components such as circulating cells, microRNAs, exosomes, and cell-free DNA have recently been gaining attention. Because of the size of the datasets generated by these omic approaches and their complexity, artificial intelligence methods are being increasingly applied to decipher their meaning. There is growing interest in imaging the lung with various modalities to understand and visualize processes in the lung that lead to pulmonary vascular remodeling including high resolution computed tomography, Xenon magnetic resonance imaging, and positron emission tomography. Such imaging modalities have the potential to demonstrate disease modification resulting from therapeutic interventions. Because right ventricular function is a major determinant of prognosis, imaging of the right ventricle with echocardiography or cardiac magnetic resonance imaging plays an important role in the evaluation of patients and may also be useful in clinical studies of pulmonary arterial hypertension.

Indexed as

biomarkergenomics–metabolomics–proteomicsimagingpharmacogenomicspulmonary arterial hypertension

Identifiers

PMID33282185
PMCPMC7682212

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.